<DOC>
	<DOCNO>NCT00384150</DOCNO>
	<brief_summary>This Phase III , multicenter , global , open-label , single-arm , retreatment study investigational drug call galiximab combination approve drug call rituximab subject relapse refractory , follicular NHL demonstrate response Study 114-NH-301 time-to-progression &gt; =6 month .</brief_summary>
	<brief_title>Retreatment Study Galiximab + Rituximab Follicular Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Demonstrated response ( CR , CRu , PR ) Study 114NH301 ( Galiximab combination Rituximab compare Rituximab combination Placebo ) relapse progress TTP &gt; =6 month . Relapsed disease define documented disease progression use International Workshop Response Criteria ( IWRC ) . Bidimensionally measurable disease least 1 lesion &gt; =2.0 cm single dimension . Acceptable hematologic , hepatic , renal function . Key Any lymphoma therapy Final Visit Study 114NH301 Study Day 1 retreatment study . Chronic intermittent corticosteroid inflammatory autoimmune disorder within 3 week prior Study Day 1 . Transfusiondependent subject . Presence central nervous system ( CNS ) lymphoma . Histologic transformation . Presence pleural peritoneal effusion positive cytology lymphoma . Another primary malignancy require active treatment . Serious nonmalignant disease ( e.g. , congestive heart failure , hydronephrosis ) ; active uncontrolled bacterial , viral , fungal infection ; condition would compromise protocol objective opinion Investigator and/or Sponsor . New York Heart Association Class III IV cardiac disease myocardial infarction within 6 month prior Study Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>galiximab</keyword>
	<keyword>antibody</keyword>
	<keyword>refractory</keyword>
	<keyword>follicular</keyword>
	<keyword>relapse</keyword>
	<keyword>NHL</keyword>
	<keyword>rituximab</keyword>
	<keyword>retreatment</keyword>
</DOC>